SCHÖNEFELD, Germany – June 30, 2025 – Captain T Cell, a biotech company developing next-generation TCR-T cell therapies for solid tumors, today announced that the National Center for Tumor Diseases (NCT) has awarded funding to Charité – Universitätsmedizin Berlin for an ...

BERLIN, Germany – June 17, 2025 – Captain T Cell GmbH, a biotech company developing next-generation TCR-based cell therapies for patients with solid tumors, today announced that it has been selected for residency in the Bayer Co.Lab incubator in Berlin. The Bayer Co.Lab program supports cutting-edge ...

WILMINGTON, Mass. – June 17, 2024 – Charles River Laboratories International, Inc. (NYSE: CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a plasmid DNA and retrovirus vector production program agreement. As part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program (CAP), ....

Schoenefeld/Berlin, Germany, May 22, 2024 — Captain T Cell GmbH, a biotechnology company developing next-generation T cells against solid tumors, today announced the successful closing of a seed financing round totaling € 8.5 million. A syndicate of experienced life science investors including i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH, and HIL-INVENT Ges.m.b.H participated in the round. In addition, ….